Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 1,016,794 shares at $22.71 ($23.7M) on 2024-02-20, disclosed to the SEC on 2024-02-20.
Scheduled sale ($23.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.88 | 175,793 | $4.2M | 17.7% |
| 2 | $23.88 | 175,793 | $4.2M | 17.7% |
| 3 | $24.45 | 2,113 | $52K | 0.2% |
| 4 | $24.45 | 2,113 | $52K | 0.2% |
| 5 | $23.14 | 162,707 | $3.8M | 15.9% |
| 6 | $23.14 | 162,707 |
| $3.8M |
| 15.9% |
| 7 | $22.71 | 166,029 | $3.8M | 15.9% |
| 8 | $22.71 | 166,029 | $3.8M | 15.9% |
| 9 | $23.40 | 3,510 | $82K | 0.3% |
| Total | $23.26 avg | 1,016,794 | $23.7M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |